Cambridge AI startup Blitzy raised $200M at a $1.4B valuation to scale its agentic platform that rewrites legacy corporate code. Boston investors joined the round as the company hires in Kendall Square.

An AI from Mass General Brigham and MIT can score lung‑cancer risk from one CT up to six years ahead; the model is validated but not yet cleared for routine care.

Vertex and Moderna said Monday they are discontinuing the VX‑522 Phase 1/2 inhaled mRNA trial after persistent lung inflammation concerns, ending a potential option for thousands of CF patients.

A Harvard‑led Science paper found an OpenAI reasoning model outscored physicians on several text‑based diagnostic tasks, but authors say randomized trials are needed before clinical use.

Mass General Brigham and Dana‑Farber are expanding early‑detection clinics in Boston, drawing new gifts and system investment — and raising fresh debate about overdiagnosis and cost.

Boston is hosting its first Climate Week (May 3–10), folding a two‑day ClimaTech summit into a citywide run of panels, demos and investor programming. Organizers say the week pairs neighborhood events with opportunities to scale climate startups.

Boston life‑sciences chiefs reported multimillion‑dollar pay in 2025 — the top executive earned $23.5M — even as the sector shed thousands of jobs. The contrast highlights growing attention on pay practices in the region.

Avalyn’s Nasdaq debut raised about $300M and the stock jumped 64% to close at $29.49 as the company advances inhaled therapies for pulmonary fibrosis.

Biogen beat Q1 estimates as Leqembi sales surged 74% to $168M, but the company trimmed full‑year EPS after booking deal‑related charges tied to the Apellis purchase.

Cambridge-based Axoft says it temporarily implanted its Fleuron brain probe in a Shanghai patient and closed a $55M Series A to expand trials and scale manufacturing.

Charles Lieber, convicted in 2021, now heads i‑BRAIN in Shenzhen with a new ASML nanofab and primate infrastructure — a move that raises policy and security questions.

Baystate Health will transition Mercy Medical Center in Springfield into its system under a definitive agreement meant to stabilize operations. The move is subject to regulatory approval and the transition is slated for Nov. 1, 2026.

Cambridge-based Hemab filed to raise $212M in a Nasdaq IPO to advance clinical programs for rare bleeding disorders. The S-1 outlines uses for sutacimig and HMB-002.